GlassScriptPhysician profile
Tara Mccabe
NPI 1972962504
$22,309.46
in general payments reported to CMS, 2019-2025
13 companies · $1,419 in 2025
The $1,419 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $204 · 2022: $2,563 · 2023: $17K · 2024: $1,147 · 2025: $1,419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,860 · Consulting Fee: $5,570 · Travel and Lodging: $3,813 · Food and Beverage: $1,121 · Education: $178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,860.00 |
| Consulting Fee | $5,570.00 |
| Travel and Lodging | $3,813.13 |
| Food and Beverage | $1,120.96 |
| Education | $178.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $19,467.25 | 2022-2025 | Adcetris |
| Pfizer INC. | $1,387.43 | 2024-2025 | |
| Genmab U.S., INC. | $980.00 | 2025 | Epkinly |
| Incyte Corporation | $116.23 | 2022 | |
| Jazz Pharmaceuticals INC. | $76.34 | 2021 | |
| Astellas Pharma US INC | $73.99 | 2022 | |
| Alexion Pharmaceuticals, INC. | $49.59 | 2021 | |
| Amgen INC. | $44.71 | 2021 | |
| Adaptive Biotechnologies Corporation | $43.76 | 2023 | Clonoseq |
| Abbvie INC. | $21.34 | 2025 | |
| Rigel Pharmaceuticals, INC. | $18.42 | 2021 | |
| Novartis Pharmaceuticals Corporation | $15.40 | 2023 | |
| Daiichi Sankyo INC. | $15.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tara Mccabe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.